AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 18, 2020 at 11:12 PM.

  1. #1 cafead, Nov 18, 2020 at 11:12 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,956
    Likes Received:
    3
    via AstraZeneca’s P2Y12 receptor antagonist Brilinta reduced the rate of stroke and death in a prespecified, high-risk subgroup, according to new analysis of the phase III THALES trial.

    article source
     
    Quote

Reply to Thread